Ironwood Pharmaceuticals has initiated two Phase III clinical trials to assess the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD).
Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors (PPIs), the current standard of care.
“We are excited to advance development of IW-3718 by initiating the Phase III trials,” said Christopher Wright, M.D., Ph.D., senior vice president, global development and chief development officer at Ironwood.
“Pre-clinical and clinical evidence suggest that IW-3718 may offer a treatment option for the millions of patients with GERD who continue to experience frequent and bothersome symptoms such as heartburn and regurgitation despite taking PPIs. Our teams have done excellent work to rapidly initiate these trials. We are hopeful that these studies will generate data in support of a potential approval as quickly as possible.”
The Phase III program comprises two identical randomized, double-blind, placebo-controlled, multicenter Phase III trials that target enrolling approximately 1,320 patients total (660 in each trial) with persistent GERD who demonstrate evidence of pathological acid reflux.
Eligible patients will continue to take PPIs and be randomized to placebo or IW-3718 1500 mg twice a day for eight weeks.
The primary endpoint is overall heartburn responder, defined as a patient who experiences at least a 45% reduction from baseline in heartburn severity (an improvement determined to be clinically meaningful based on patient-reported outcomes in the Phase IIb trial) for at least four out of eight weeks, including at least one of the last two weeks. Secondary endpoints include change in weekly heartburn severity, change in weekly regurgitation frequency and the proportion of heartburn-free days.
Data from the 280 patient IW-3718 Phase IIb trial in patients with persistent GERD showed that 1500 mg twice daily as an adjunct therapy to PPIs significantly reduced heartburn severity and showed reductions in frequency of regurgitation – two of the most bothersome and frequent symptoms of GERD – compared to a PPI alone.
The most common adverse event reported overall in the Phase IIb trial was constipation (IW-3718 + PPI = 7.4% vs. PPI alone = 7.1%); all constipation adverse events reported were mild or moderate in severity. Discontinuation rates due to adverse events were less than 5% and similar across treatment groups.
IW-3718 is a novel, gastric retentive formulation of colesevelam, a bile acid sequestrant, developed by Ironwood using the proprietary Acuform® drug delivery formulation technology licensed from Depomed, Inc. IW-3718 is designed to deliver the bile acid sequestrant to the stomach over an extended period where it is positioned to intercept bile before it reaches the esophagus.
Data from non-clinical and clinical studies collectively support the extended release and gastric-retentive profile of IW-3718. Ironwood has existing patents and pending patent applications for IW-3718 that are expected to provide patent coverage into the mid-2030s.
Source: Company Press Release